Diagnosis and management of drug-associated interstitial lung disease

Symptoms of drug-associated interstitial lung disease (ILD) are nonspecific and can be difficult to distinguish from a number of illnesses that commonly occur in patients with non-small-cell lung cancer (NSCLC) on therapy. Identification of drug involvement and differentiation from other illnesses is problematic, although radiological manifestations and clinical tests enable many of the alternative causes of symptoms in advanced NSCLC to be excluded. In lung cancer patients, high-resolution computed tomography (HRCT) is more sensitive than a chest radiograph in evaluating the severity and progression of parenchymal lung disease. Indeed, the use of HRCT imaging has led to the recognition of many distinct patterns of lung involvement and, along with clinical signs and symptoms, helps to predict both outcome and response to treatment. This manuscript outlines the radiology of drug-associated ILD and its differential diagnosis in NSCLC. An algorithm that uses clinical tests to exclude alternative diagnoses is also described

Suppression of non-prompt J/psi, prompt J/psi, and Upsilon(1S) in PbPb collisions at root s(NN)=2.76 TeV

Yields of prompt and non-prompt J/ψ, as well as Y(1S) mesons, are measured by the CMS experiment via their μ +μ - decays in PbPb and pp collisions at √/s NN = 2.76 TeV for quarkonium rapidity |y| < 2.4. Differential cross sections and nuclear modification factors are reported as functions of y and transverse momentum pT, as well as collision centrality. For prompt J/ψ with relatively high pT (6.5 < pT < 30 GeV/c), a strong, centrality-dependent suppression is observed in PbPb collisions, compared to the yield in pp collisions scaled by the number of inelastic nucleon-nucleon collisions. In the same kinematic range, a suppression of non-prompt J/ψ, which is sensitive to the in-medium b-quark energy loss, is measured for the first time. Also the low-pT Y(1S) mesons are suppressed in PbPb collisions. © CERN